"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."
"Our recently launched e-commerce site for Marley Drug has huge potential and will be our most significant driver of growth and major source of our profits moving forward."
"Our fixed-price, fastest DNA-to-IND program is packaged in a standardized platform to allow clients to bring a new antibody molecule to IND filing in a rapid amount of time."
"The focus of our integrated Translational Pharmaceutics programs is to provide the customer with a development platform capable of responding in real-time to emerging development data and maintain an overall timeline to proof of concept."
"We were excited to secure equity investment from Signet Healthcare Partners and have since almost doubled in size in both our capacity and talent pool."
"Insmed developed a drug-device combination that became the first approved therapy to treat patients with a refractory form of a rare and serious lung infection."
Featuring insights from nearly 50 mining executives, the second pre-release edition of GBR's Peru Mining 2025 sheds light on the industry's current state while highlighting the country's window of opportunity with the energy transition and copper's critical role.